NCT01296932View on ClinicalTrials.gov

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 11, 2011

Primary Completion Date

May 30, 2017

Study Completion Date

July 10, 2017

Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
DRUG

BI 836826

Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.

Trial Locations (10)

1200

Brussels - UNIV Saint-Luc, Brussels

2650

Edegem - UNIV UZ Antwerpen, Edegem

9000

UNIV UZ Gent, Ghent

13273

INS Paoli-Calmettes, Marseille

31059

INS Universitaire du Cancer, Toulouse

34295

CTR Investigation Clinique, onco, Montpellier, Montpellier

50937

Universitätsklinikum Köln (AöR), Cologne

60590

Universitätsklinikum Frankfurt, Frankfurt am Main

69120

Universitätsklinikum Heidelberg, Heidelberg

89081

Universitätsklinikum Ulm, Ulm

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT01296932 - BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL) | Biotech Hunter | Biotech Hunter